Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study.

Anil K Agarwal Prabir Roy-Chaudhury Phoebe MountsElizabeth HurlburtAntony PfaffleEugene C Poggio

Published in: Clinical journal of the American Society of Nephrology : CJASN (2023)

Taurolidine/heparin reduced risk of developing a CRBSI in study participants receiving hemodialysis via CVC compared with heparin with a comparable safety profile.

Keyphrases

venous thromboembolism
double blind
growth factor
end stage renal disease
peritoneal dialysis
chronic kidney disease
placebo controlled
clinical trial
open label
study protocol
escherichia coli
ultrasound guided
phase iii
phase ii
multidrug resistant